Recent Finacing
Recent Raise
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing STS101, a self-administered dry‑powder dihydroergotamine nasal delivery system optimized for rapid intranasal absorption to treat acute migraine.
